NCT06717191View on ClinicalTrials.gov

Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan

PHASE4CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

June 15, 2024

Study Completion Date

August 2, 2024

Conditions
Type 1 Diabetes
Interventions
DRUG

biosimilar insulin glargine

Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe

Trial Locations (1)

74600

Baqai Institute of Diabetology and Endocrinology (BIDE), Karachi

All Listed Sponsors
collaborator

Baqai Institute of Diabetology and Endocrinology

OTHER

lead

Life for a Child Program, Diabetes Australia

OTHER